Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.
In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; manufacturing and other costs; the therapeutic and commercial potential of Stimuvax and other product candidates; future clinical development plans for various product candidates; the details of the clinical trials for various product candidates; the anticipated future size of the market for Stimuvax; and identifying and capitalizing on possible collaboration, strategic partnering, acquisition or divestiture opportunities. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.
Forward-looking statements involve risks and uncertainties, including
risks and uncertainties
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved